Report Categories Report Categories

Report Categories

industry Category

All

Total: 2 records, 1 pages

Global Antisense Oligonucleotides Drugs for ATTR Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 13 Aug 2024

date Pharma & Healthcare

new_biaoQian Antisense Oligonucleotides Drugs for ATTR

Antisense oligonucleotide(ASO)drugs represent a groundbreaking approach for treating transthyretin amyloidosis(ATTR),a condition characterized by the accumulation of misfolded transthyretin proteins that lead to organ damage.These ASO drugs work by targeting and degrading the mRNA that encodes for transthyretin,thus reducing its production at the source.

USD3480.00

Add To Cart

Add To Cart

Global Antisense Oligonucleotides Drugs for ATTR Supply, Demand and Key Producers, 2024-2030

date 13 Aug 2024

date Pharma & Healthcare

new_biaoQian Antisense Oligonucleotides Drugs for ATTR

Antisense oligonucleotide(ASO)drugs represent a groundbreaking approach for treating transthyretin amyloidosis(ATTR),a condition characterized by the accumulation of misfolded transthyretin proteins that lead to organ damage.These ASO drugs work by targeting and degrading the mRNA that encodes for transthyretin,thus reducing its production at the source.

USD4480.00

Add To Cart

Add To Cart

industry 13 Aug 2024

industry Pharma & Healthcare

new_biaoQian Antisense Oligonucleotides Drugs for ATTR

Antisense oligonucleotide(ASO)drugs represent a groundbreaking approach for treating transthyretin amyloidosis(ATTR),a condition characterized by the accumulation of misfolded transthyretin proteins that lead to organ damage.These ASO drugs work by targeting and degrading the mRNA that encodes for transthyretin,thus reducing its production at the source.

USD3480.00

addToCart

Add To Cart

industry 13 Aug 2024

industry Pharma & Healthcare

new_biaoQian Antisense Oligonucleotides Drugs for ATTR

Antisense oligonucleotide(ASO)drugs represent a groundbreaking approach for treating transthyretin amyloidosis(ATTR),a condition characterized by the accumulation of misfolded transthyretin proteins that lead to organ damage.These ASO drugs work by targeting and degrading the mRNA that encodes for transthyretin,thus reducing its production at the source.

USD4480.00

addToCart

Add To Cart